Home » Stocks » RNAZ

TransCode Therapeutics, Inc. (RNAZ)

Stock Price: $3.39 USD 0.30 (9.71%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Pre-market: $3.33 -0.06 (-1.77%) Jul 26, 8:09 AM
Market Cap 40.57M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 11.97M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $3.39
Previous Close $3.09
Change ($) 0.30
Change (%) 9.71%
Day's Open 3.08
Day's Range 3.04 - 3.45
Day's Volume 513,894
52-Week Range 2.67 - 7.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), an emerging RNA oncology company created on the belief that cancer can be defeated through the intell...

1 week ago - Business Wire

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics IPO Pricing Release

2 weeks ago - Business Wire

Transcode Therapeutics, a preclinical biotech developing RNA-based therapies for cancer, filed on Friday with the SEC to raise up to $30 million in an initial public offering.

4 months ago - NASDAQ

TransCode Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About RNAZ

TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. Our strategy seeks to overcome RNA-based therapeutics delivery challenges by repurposing a particle used extensively in humans for imaging purposes to deliver synthetic RNA molecules (called oligonucleotides) to cancer cells. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving pat... [Read more...]

Industry
Biotechnology
IPO Date
Jul 9, 2021
CEO
R. Michael Dudley
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
RNAZ
Full Company Profile

Financial Performance

Financial Statements